Progress towards an OMERACT-ILAR guideline for economic evaluations in rheumatology.
A working report from the OMERACT Health Economics Group. The group is working towards creating common standards for economic evaluation in rheumatology and also towards improving the scientific underpinning of economic evaluation, particularly pertaining to the rheumatic diseases. Preliminary recommendations for "reference cases" in osteoporosis, rheumatoid arthritis, and osteoarthritis are proposed.
Gabriel
S E
SE
Department of Health Sciences Research and Division of Rheumatology, Mayo Clinic, Rochester, MN 55905, USA. gabriel.sherine@mayo.edu
Tugwell
P
P
Drummond
M
M
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000191:economics / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000191:economics / Q000627:therapeutic use*; D016527:Drug Costs; D006801:Humans; D017410:Practice Guidelines as Topic; D015397:Program Evaluation; D012216:Rheumatic Diseases / Q000188:drug therapy* / Q000191:economics
D000894:Anti-Inflammatory Agents, Non-Steroidal; D018501:Antirheumatic Agents